StockNews.com Downgrades XOMA (NASDAQ:XOMA) to Sell

StockNews.com lowered shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a report released on Friday morning.

Separately, HC Wainwright reissued a “buy” rating and issued a $123.00 price objective on shares of XOMA in a research report on Friday, December 13th.

XOMA Trading Down 3.6 %

Shares of XOMA stock opened at $26.30 on Friday. The company has a market capitalization of $309.89 million, a price-to-earnings ratio of -7.56 and a beta of 0.88. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm has a 50-day moving average price of $29.82 and a 200 day moving average price of $27.80. XOMA has a twelve month low of $18.24 and a twelve month high of $35.00.

Insiders Place Their Bets

In other XOMA news, CEO Owen Hughes sold 21,881 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On XOMA

Large investors have recently modified their holdings of the company. Geode Capital Management LLC increased its position in shares of XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after acquiring an additional 1,138 shares in the last quarter. State Street Corp boosted its position in XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 1,754 shares during the period. Bank of New York Mellon Corp increased its holdings in XOMA by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares in the last quarter. Ellsworth Advisors LLC acquired a new stake in XOMA in the 3rd quarter valued at $516,000. Finally, Barclays PLC raised its position in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares during the period. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.